Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Immuron (IMRN) Long-Term Debt Repayments (2016 - 2020)

Immuron's quarterly Long-Term Debt Repayments came in at -$212794.0 in Q4 2020, up 20.76% year-on-year from -$176216.1 in Q1 2020, and up 20.76% quarter-over-quarter from -$268535.0 in Q4 2019.

Immuron has reported Long-Term Debt Repayments for 4 years, with the latest figure at -$212794.0 in Q4 2020.

  • For the quarter ending Q4 2020, Long-Term Debt Repayments rose 20.76% year-over-year to -$212794.0; the trailing twelve-month figure through Dec 2020 stood at $287274.9 (changed N/A YoY), and the FY2021 full-year result was -$155020.6, up 42.16% from the prior year.
  • Long-Term Debt Repayments for Q4 2020 stood at -$212794.0, up from -$268535.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $958724.5 in Q4 2016, with the low at -$268535.0 in Q4 2019.
  • Average Long-Term Debt Repayments over 4 years is $71818.7, with a median of -$201457.3 recorded in 2017.
  • Year-over-year, Long-Term Debt Repayments sank 119.83% in 2017 and gained 20.76% in 2020.
  • Tracing IMRN's Long-Term Debt Repayments over 4 years: stood at $958724.5 in 2016, then tumbled by 119.83% to -$190120.6 in 2017, then plunged by 41.24% to -$268535.0 in 2019, then increased by 20.76% to -$212794.0 in 2020.
  • The last three Long-Term Debt Repayments figures came in at -$212794.0 (Q4 2020), -$268535.0 (Q4 2019), and -$190120.6 (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 -212,794.00
Dec 31, 2020 -212,794.00
Dec 31, 2019 -268,535.00
Dec 31, 2019 -268,535.00
Dec 31, 2017 -190,120.62
Dec 31, 2017 -190,120.62
Dec 31, 2016 958,724.53
Dec 31, 2016 958,724.53